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Abstract
 
Osteoclasts (OCs) are multinucleated cells that resorb bone and are essential for bone homeo-
stasis. They develop from hematopoietic cells of the myelomonocytic lineage. OC formation
requires cell-to-cell interactions with osteoblasts and can be achieved by coculturing bone
marrow precursor cells with osteoblasts/stromal cells. Two of the key factors mediating the
osteoblast-induced osteoclastogenesis are macrophage–colony stimulating factor (M-CSF) and
the tumor necrosis factor (TNF) family member TNF–related activation-induced cytokine
(TRANCE) that are produced by osteoblasts/stromal cells in response to various bone resorb-
ing hormones. In addition, other factors produced by osteoblasts/stromal cells further influence
osteoclastogenesis. Here we report the identification and characterization of OC-associated re-
ceptor (OSCAR), a novel member of the leukocyte receptor complex (LRC)-encoded family
expressed specifically in OCs. Genes in the LRC produce immunoglobulin (Ig)-like surface re-
ceptors and play critical roles in the regulation of both innate and adaptive immune responses.
Different from the previously characterized members of the LRC complex, OSCAR expres-
sion is detected specifically in preosteoclasts or mature OCs. Its putative–ligand (OSCAR-L)
is expressed primarily in osteoblasts/stromal cells. Moreover, addition of a soluble form of
OSCAR in coculture with osteoblasts inhibits the formation of OCs from bone marrow pre-
cursor cells in the presence of bone-resorbing factors, indicating that OSCAR may be an im-
portant bone-specific regulator of OC differentiation. In addition, this study suggests that
LRC-encoded genes may have evolved to regulate the physiology of cells beyond those of the
immune system.
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Introduction
 
Bones provide rigid support for the body, mechanical in-
tegrity of movement and protection, and serve as a site of
mineral homeostasis. Additionally, bone is an indispensable
connective tissue as well as the primary site for hemato-
poiesis. Bone is continuously remodeled through new bone
formation by osteoblasts and the resorption of old bone by
osteoclasts (OCs)
 
*
 
 which provides the renewal of the skele-
ton with structural and functional integrity. Normal skele-
tal formation and maintenance, and mineral homeostasis
are thus maintained by the coupled actions of two principal
cell types in bone, osteoblasts, and OCs (1, 2).
OCs, the only cells capable of resorbing bone, are derived
from the same bone marrow precursor cells of the mono-
cyte-macrophage lineage that give rise to macrophages and
dendritic cells (DCs) (1, 2). For OC differentiation and acti-
vation of mature OCs, osteoblasts play an obligatory role by
providing essential osteoclastogenesis factors in response to
bone resorbing hormones (1, 2).
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There are at least two essential factors provided by os-
teoblasts to support osteoclastogenesis that are macro-
phage–colony stimulating factor (M-CSF) and TNF–related
activation-induced cytokine (TRANCE). Spontaneous os-
teopetrotic mice (op/op) which are deficient in M-CSF show
defective OC development. Osteoblasts derived from
M-CSF–deficient mice failed to support osteoclastogenesis,
indicating that M-CSF produced by osteoblasts is essential for
differentiation of OCs from bone marrow precursors (1–4).
The TNF family member TRANCE, which is expressed in
osteoblasts in response to various bone-resorbing hormones,
is also required for osteoclastogenesis (1, 2, 5–8). Similar to
the case of M-CSF–deficient osteoblasts, TRANCE-defi-
cient osteoblasts failed to support osteoclastogenesis. These
results clearly indicate that M-CSF and TRANCE are re-
quired for OC differentiation. TRANCE or M-CSF ex-
pression on osteoblasts is not constitutive but regulated by
various bone-resorbing hormones (e.g., the active form of
vitamin D
 
3
 
, 1
 
 
 
,25-dihydroxyvitamin D
 
3
 
, 1
 
 
 
,25(OH)
 
2
 
D
 
3
 
and parathyroid hormone) or cytokines (e.g., IL-1 and
TNF), suggesting that a number of cytokines and hormones
indirectly regulate osteoclastogenesis in part by controlling
the expression of TRANCE or M-CSF on osteoblasts (1, 2,
9, 10). Bone marrow cells or spleen cells can differentiate
into bone-resorbing mature OCs in the absence of osteo-
blasts/stromal cells when recombinant M-CSF and TRANCE
are added in the culture. Thus, M-CSF and TRANCE to-
gether are not only necessary but also sufficient factors for
OC development, and they are likely to be responsible for
most of the obligatory roles provided by osteoblast for os-
teoclastogenesis (1, 2).
Although it is clear that M-CSF and TRANCE are two
most important factors regulating osteoclastogenesis, other
cytokines (e.g., IL-1, INF-
 
 
 
, TGF-
 
 
 
) have also been
shown to regulate OC differentiation or activity directly (1,
2, 11–17). It is not clear how those cytokines modulate the
OC differentiation or activity, but they are likely to act in
conjunction with M-CSF and/or TRANCE.
Most of factors described to date, including M-CSF and
TRANCE, that affect the fate of OCs (differentiation, activa-
tion, and survival) also influence macrophages or DCs which
share their bone marrow precursors during development
(18). Therefore, it appears that there are considerable molec-
ular overlaps between OCs and cells of the immune system
such as macrophages and DCs. In this paper, we have at-
tempted to further investigate the commonality and unique-
ness of OCs compared with their relatives such as macro-
phages or DCs by exploring mRNA expression profiles in
these cells. Here we have identified a novel member of leu-
kocyte receptor complex (LRC)-encoded protein which is
expressed specifically on OC-lineage cells and show that this
novel LRC-family member regulates osteoclastogenesis.
 
Materials and Methods
 
Cell Culture and Poly A
 
 
 
 RNA Preparation.
 
OCs: murine (OCs)
were derived as described previously (19). In brief, bone mar-
row–derived cells (10
 
7
 
/100 mm dish) from C57BL/6 mice (4–6
wk of age) were incubated with human M-CSF (5 ng/ml) in
 
 
 
-MEM/10% FCS for 16 h. After incubation, the floating cells
were collected and further cultured with 30 ng/ml of M-CSF,
1 
 
 
 
g/ml of soluble murine TRANCE, and PGE
 
2
 
 (10
 
 
 
6
 
 M) for 4 d.
On day 3, the culture was changed with fresh media. On day 4,
the cells were washed with PBS, and harvested. Human OCs are
generated as described previously (20). Total RNA was prepared
by TRIZOL reagent (GIBCO BRL). 1 mg of total RNA was
subjected into Oligotex poly A
 
 
 
 RNA column (QIAGEN) to
purify poly A
 
 
 
 RNA. Macrophages: murine macrophages were
generated from bone marrow progenitors, using human M-CSF
(30 ng/ml; reference 19). On day 4, the cells were washed with
PBS, harvested, and subjected to poly A
 
 
 
 RNA purification as
described above. DCs: murine bone marrow–derived DCs were
generated from mouse bone marrow progenitors, using GM-CSF
as described previously (21). On day 8, the mature bone marrow–
derived DCs were washed with PBS, and harvested. RNA was
prepared as described above. RAW264.7: the murine myeloid
RAW264.7 cell line (American Type Culture Collection) was
maintained with DMEM/10% FCS containing 1 mM sodium
pyruvate and 10 mM Hepes. To generate OCs, the cells (5 
 
 
 
 10
 
5
 
cells per 100-mm dish) were cultured with 1 
 
 
 
g/ml of recombi-
nant soluble TRANCE for 4 d. On day 3, the culture was
changed with fresh media. To prepare poly A
 
 
 
 RNA, the cells
were washed with PBS, harvested, and subjected to poly A
 
 
 
RNA purification as described above.
 
OC-enriched cDNA Library, PCR-Subtraction, and Full-Length
cDNA Cloning.
 
An OC-enriched cDNA library was generated
by using poly A
 
 
 
 RNA from OCs and macrophages (MØs) as
described previously (22). In brief, 2 
 
 
 
g of poly A
 
 
 
 RNA from
OCs and MØs was used to make tester and driver cDNAs, re-
spectively. Subtractive PCR was performed using the PCR-
select cDNA subtraction kit according to the manufacturer’s proto-
col (CLONTECH). Around 250 clones from this cDNA library
were tested in this study and OCL178 encoding amino acid resi-
dues 161–265 of murine OC-associated receptor (OSCAR) was
isolated. To clone full-length OSCAR cDNA, cDNA fragments
of OSCAR derived from OC-enriched cDNA library were used
to screen a 
 
 
 
ZAP cDNA library derived from mouse OCs and
human OCs. Two mRNA species for OSCAR seen in Northern
blot analysis are from alternatively spliced forms of OSCAR
mRNAs. Two forms differ only in the 3
 
 
 
 untranslated region.
 
OC Formation Assay and Pit Formation Assay.
 
For OC forma-
tion culture, primary calvarial osteoclasts were obtained from calva-
riae of newborn C57BL/6 mice by conventional method using
collagenase, and bone marrow cells were obtained from the femora
and tibiae of 4–7-wk-old C57BL/6 male mice (23). Calvarial os-
teoblasts (10
 
4
 
 cells) and bone marrow cells (10
 
5
 
 cells) were cocul-
tured in the presence or absence of 10
 
 
 
8
 
 M 1,25(OH)
 
2
 
D
 
3
 
 in 0.2 ml
minimum essential medium 
 
 
 
 medium (
 
 
 
-MEM) containing 10%
FBS in 96-well culture plates. After 5, 6, or 7 d of culture, cells
were fixed and stained for tartrate-resistant acid phosphatase
(TRAP) as described previously (23). TRAP-positive multinucle-
ated cells were counted as OC-like multinucleated cells. To deter-
mine the pit-forming activity of OCs, calvarial osteoblasts (10
 
4
 
cells) and bone marrow cells (10
 
5
 
 cells) were cocultured in the pres-
ence or absence of 10
 
 
 
8
 
 M 1,25(OH)
 
2
 
D
 
3
 
 on dentine slices (0.2–0.3
mm in thickness, 4 mm in diameter) placed in 96-well culture
plates for 6 d as described previously (23). The slices were then re-
covered, cleaned by ultrasonication in 0.5 M NH
 
4
 
OH to remove
adherent cells, and stained with Mayer’s hematoxylin (Sigma-
Aldrich) to visualize resorption pits. The numbers of pits on slices 
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were counted by microscope observation. Some cultures were
treated with OSCAR-Fc, human IgG or TRANCE-R-Fc (24).
Media of each culture were replaced with fresh media every 3 d.
 
A Soluble Form of OSCAR and Anti-OSCAR mAb.
 
A solu-
ble form of OSCAR was produced as an OSCAR–Fc fusion pro-
tein, in which the entire extracellular domain (amino acid residues
1–228) was fused in frame to the constant region of human IgG1.
OSCAR-Fc protein was produced in insect cells, and purified by
Protein A affinity chromatography as described previously (24).
Purified OSCAR–Fc was then used to immunize rats to generate
mAbs against murine OSCAR as described previously (8).
 
Northern Blot Analysis.
 
Total RNA (10 
 
 
 
g) or poly A
 
 
 
 RNA
(0.5 
 
 
 
g) was separated and transferred to nylon membranes as de-
scribed previously (22). The membranes were hybridized with
 
32
 
[P]dCTP probe prepared using Ready-to-Go labeling kit and
ProbeQuant G-50 purification kit (Amersham Pharmacia Biotech).
 
Chromosome Mapping of OSCAR.
 
The contiguous map of
mouse OSCAR was identified using radiation hybrid (RH) map-
ping kit (Research Genetics) following the manufacturer’s instruc-
tions. In brief, two types of primer sets were designed from 3
 
 
 
 un-
translated region of mouse OSCAR cDNA. The primers used
were as follows: primer set #1 (5
 
 
 
AGA TGG ACA GAG AAG
CTG GGATCC3
 
 
 
 and 5
 
 
 
TTA GGA GCC AGC CAG ATG
GCT CAG3
 
 
 
), and primer set #2 (5
 
 
 
AAG GGT AAT ACC
CAG GCC TCA GCC3
 
 
 
 and 5
 
 
 
AAG AGT ACT GGC TAC
TCT TCT AGA3
 
 
 
). Genomic DNA PCR was performed for 30
cycles (94
 
 
 
C, 30 s; 55
 
 
 
C, 30 s; 72
 
 
 
C, 30 s). RH data of murine
OSCAR genomic PCRs were analyzed by The Jackson Labora-
tory (http://www.jax.org/). The RH data showed mouse OS-
CAR location in chromosome 7 near paired Ig-like receptor
(PIR) genes. Human BAC clone (AC009968.6) containing hu-
man OSCAR genomic sequences was identified in the human ge-
nome database by blast search. Chromosome location was identi-
fied in the NCBI Entrez browser.
 
Results and Discussion
 
OCs are the only cells capable of resorbing bone, al-
though they are derived from the same bone marrow pre-
cursor cells of the monocyte-macrophage lineage that give
rise to macrophages and DCs (1, 2). To provide insight
into how OCs differentiate and function to control bone
homeostasis, we have compared mRNA expression profiles
between mature OCs and macrophages (MØ), two closely
related cell types, by PCR-select cDNA subtraction. A
subtraction cDNA library (OC-MØ) was constructed and
analyzed as described previously (22), and one clone
(OCL178 that contains a partial cDNA fragment of the
gene that we have called OSCAR) was chosen for further
analysis in this study.
To test whether OSCAR is derived from a gene specifi-
cally expressed in OCs, mRNA from OCs and MØs was
used for Northern blot analysis (Fig. 1 A). OSCAR frag-
ment detected two distinct mRNA species (1.8 kb and 1.0
kb) that were specifically expressed in bone marrow–
derived OCs but not in bone marrow–derived MØs.
Moreover, OSCAR mRNA expression was not detected in
bone marrow–derived DCs which differentiate from the
same bone marrow precursor cells of the monocyte-mac-
rophage lineage that give rise to MØs and OCs. As re-
ported previously, TRAP or cathepsin K expression was
detected in OCs but not in MØs (1, 2). However, unlike
OSCAR, TRAP, or cathepsin K was also detected in DCs,
albeit at low levels. Thus OSCAR mRNA expression is
much more specific for OCs than TRAP or cathepsin K.
In addition to bone marrow–derived OCs, OSCAR ex-
pression was also detected in OC-like cells derived from
Figure 1. OSCAR mRNA expression. (A)
Northern blot analysis of RNA from bone
marrow–derived OCs OC, macrophages
(MØ), and DCs. GAPDH was used as con-
trol. (B) OSCAR mRNA expressions during
the differentiation of RAW264.7 to mature
OCs by TRANCE. Northern blot analysis
was performed using total RNA from
RAW264.7 cells stimulated with recombi-
nant TRANCE (200 ng/ml) for 0–4 d.
OSCAR, TRAP, Cathepsin K, and GAPDH
were used for probes. (C and D) Northern
blot analysis of OSCAR in various mouse tis-
sues and bone marrow–derived OCs. 
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the RAW264.7 cell line. As reported, RAW264.7 cells can
be differentiated into OC-like cells by treatment of the
TNF family member TRANCE (25). Here we showed
that OSCAR expression could be easily detected 72 h af-
ter stimulation of RAW264.7 cells with recombinant
TRANCE, and its expression was highest when RAW264.7
cells were completely differentiated into OCs (4 d after
TRANCE stimulation) (Fig. 1 B). However, under more
sensitive conditions, OSCAR mRNA was also detected
during OC differentiation before no mature OCs were
visibly detected in the culture (48 h after stimulation with
TRANCE; data not shown), suggesting that some OC dif-
ferentiation intermediates might express OSCAR.
To further determine the specificity of OSCAR mRNA
expression, mRNAs from various tissues were analyzed by
Northern blot analysis. OSCAR mRNA expression was not
detected in any soft tissues tested (Fig. 1 C). However, OS-
CAR mRNA could be detected when mRNA was pre-
pared from OC-rich tissues such as skull or long bones (Fig.
1 D). In comparison, TRAP or cathepsin K mRNA, which
Figure 2. Sequence analysis of OSCAR. (A) The predicted amino acid sequence of the full-length murine OSCAR protein (mOSCAR) compared
with that of human OSCAR (hOSCAR). Dots indicate shared identities between mouse and human protein, and dashes indicate gaps between regions
of homology. The boldface letters indicate the position of the conserved cysteine in the Ig-fold. Residues labeled with an asterisk (*) indicate potential
NH2-linked glycosylation sites. The numbers in left-hand column indicate the amino acid residue positions in the mOSCAR and hOSCAR protein. Be-
tween L12 and W13 of mOSCAR, six amino acids(CELSLP) are inserted by alternative splicing in the minor population of mOSCAR cDNA clones.
Also, 1 of 15 clones of hOSCAR has a four amino acid (AIIV) insertion between V24 and P25 of hOSCAR and 2 of 15 clones of hOSCAR have a de-
letion of 11 amino acids (residues 13 through 24, WPLCHTDITPSV, are replaced with F13) by alternative splicing. GenBank accession nos. for
mOSCAR are AF391159, AF391160, and AF391161 and for hOSCAR are AF391162, AF391163, and AF391164. (B) The sequence comparison of
the two Ig-like domains of hOSCAR with other members of the LRC-encoded genes: hIGSF(AF034198), hKIR(AF072410), hILT1(U82275), and
hGPVI(AB035073). Gaps in alignment are indicated by dashes and identical amino acids appear on a dark background. The numbers in the left-hand
column indicate the residue positions from the full-length protein sequences. 
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were considered to be markers for OCs, could be detected in
mRNA derived from tissues other than bone. These results
thus show that OSCAR is specifically expressed in OCs,
both bone marrow–derived OCs and OCs found in vivo.
Since OSCAR expression follows TRAP or cathepsin K
during OC differentiation by two independent experimen-
tal systems (bone marrow–derived OCs and RAW264.7-
derived OCs), a potential role of OSCAR is likely to regu-
late OC function/differentiation. Therefore, we cloned
and characterized the full-length OSCAR cDNAs from
murine and human OC cDNA libraries. The full-length
OSCAR cDNA encodes a type I transmembrane protein
(Fig. 2). The extracellular domain of OSCAR contains two
Ig-like domains with significant homology to murine PIR
family proteins (26, 27) and to members of the human
LRC-encoded proteins (28–37). The predicted transmem-
brane region contains a charged Arg residue, suggesting
that OSCAR may associate with another transmembrane
protein. Mouse OSCAR (mOSCAR) is localized near the
proximal end of mouse chromosome 7, the region where
PIR family proteins reside (26), while human OSCAR
(hOSCAR) gene was found to reside in the human chro-
mosome 19q13.4, which contains the LRC (28, 37). These
results thus indicate that OSCAR is a bona fide novel
member of the PIR/LRC family proteins. The amino acid
identity between mouse and human OSCAR is 
 
 
 
73%,
which distinguishes it from other PIR-related and LRC
family proteins, most of which lack orthologs in mouse and
man. To date, in addition to OSCAR, the only PIR/LRC
family member with orthologs in humans, mice, and rats is
the p46 NK cell receptor, NKp46 (28, 37–39).
Northern blot analysis of OSCAR indicated that OS-
CAR expression was predominant in mature OCs but was
also detected during OC differentiation before mature OCs
were visibly detected in the culture, suggesting that some
OC differentiation intermediates might express OSCAR
Figure 3. Expression and regulation of OSCAR protein. (A) FACS® analysis of cell surface OSCAR expression on freshly isolated bone marrow cells
(BM), bone marrow–derived MØ (BM-MØ), and OCs (BM-OC). After differentiation, cells were stained with anti-OSCAR mAb (open histogram) or
isotype control mAb (shaded histogram). (B) Immunohistochemistry of OSCAR on in vitro bone marrow–derived macrophage (BM-MØ) and bone
marrow–derived OC (BM-OC). For immunohistochemistry, cells were fixed with 4% paraformaldehyde, and followed by TRAP assay (left and middle),
staining with rat anti-OSCAR mAb (middle and right) or rat IgG as a control (left). TRAP-positive cells are stained red and OSCAR-expressing cells are
stained blue. 
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(Fig. 1). To further determine when OSCAR is expressed
during osteoclastogenesis, a rat anti-mOSCAR mAb was
generated and used for FACS
 
®
 
 and immunohistochemical
analysis. Surface OSCAR was detected predominantly on
mature OCs but not on other cells including macrophages,
DCs, NK cells, and lymphocytes (Fig. 3 A), consistent with
mRNA expression profiles. In addition, we showed by im-
munohistochemical analyses that a fraction of mononuclear,
TRAP-positive preosteoclasts expressed surface OSCAR,
albeit at low levels (Fig. 3 B). None of the TRAP-negative
cells expressed measurable levels of OSCAR. These results
indicate that OSCAR protein is predominantly expressed
on the surface of mature OCs as well as some cells of OC
lineage. OSCAR expression is likely to begin at an inter-
mediate stage of differentiation from TRAP-positive OC
precursors to fully mature multinucleated OCs.
Since OSCAR expression is detected in pre-OCs and
LRC family members have been shown to regulate various
functions of cells in the immune system (28, 37), we hy-
pothesized that OSCAR may be involved in the differenti-
ation of OC-precursors to mature, multinucleated OCs.
To test this hypothesis, we made a soluble form of OS-
CAR by fusing the extracellular domain of OSCAR to the
Fc portion of human IgG1 (OSCAR–Fc). To determine
the role of OSCAR in osteoclastogenesis, OSCAR-Fc was
added to a coculture of bone marrow precursor cells and
osteoblast/stromal cells in the presence of an osteotropic
factor, 1,25(OH)
 
2
 
D
 
3
 
 (Fig. 4 A–C). The addition of OS-
CAR–Fc significantly inhibited the formation of multinu-
cleated TRAP
 
 
 
 OCs in the coculture stimulated by
1,25(OH)
 
2
 
D
 
3
 
. Furthermore, when cultures were made on
dentine slices, OSCAR–Fc inhibited bone resorption as
measured by pit formation (Fig. 4 A and D). As a control,
we also used TRANCE-R-Fc to inhibit the interaction of
the TNF family member TRANCE and its receptor
(TRANCE-R/RANK), which has been previously shown
to be essential for osteoclastogenesis in the coculture system
(Fig. 4 A–D; references 1, 2, 5, 6, 18, 22, and 40). These
Figure 4. Role of OSCAR in OC differentiation. (A) A
soluble form of OSCAR inhibits OC formation from bone
marrow precursor cells in the coculture with osteoblast/stro-
mal cells in the presence of osteotropic factors. Mouse bone
marrow cells (105 cells/ per well) collected from 5–7-wk-old
male mice and mouse primary calvarial osteoblasts (104 cells
per well) collected from newborn mice were cocultured
in the presence of 10 8 M 1 ,25-dihydroxyvitamin D3
(1,25(OH)2D3) with 20  g/ml OSCAR-Fc, 20  g/ml hu-
man IgG, or 5  g/ml TRANCE-R-Fc in 96-well culture
plates (top) or on dentine slices (4 mm diameter) placed in
96-well culture plates (bottom). Cells were also cultured in
the presence of 10 8 M 1,25(OH)2D3 without any additives
as a control. On day 6, cells in 96-well culture plates were
fixed and stained for TRAP. TRAP-positive cells appeared
as red cells (top). Cells on dentine slices were removed, and
dentine slices were stained with Mayer’s hematoxylin. Pits
appeared as dark spots (bottom). Bar indicates 250  m. In
the absence of 1,25(OH)2D3, no TRAP-positive multinu-
cleated cells appeared in the coculture (data not shown). (B)
Mouse bone marrow cells and primary calvarial osteoblasts
were cocultured in the presence of 10 8 M 1,25(OH)2D3
with increasing concentrations (0, 5, 10, and 20  g/ml) of
OSCAR–Fc (black circles) or human IgG (white circles) in 96-well culture plates for 6 d. After fixing and staining cells for TRAP, numbers of TRAP-
positive multinucleated cells (MNCs) were counted as OCs. (C) Mouse bone marrow cells and mouse primary calvarial osteoblasts were cocultured in
the presence of 10 8 M 1,25(OH)2D3 with 20  g/ml OSCAR–Fc (black circles), 20  g/ml human IgG (white circles), or 5 g/ml TRANCE-R-Fc
(black triangles) in 96-well culture plates. Cells were also cultured in the presence of 10 8 M 1,25(OH)2D3 without any additives as control (white
squares). On days 0, 5, 6, and 7, cells were fixed and stained for TRAP. TRAP-positive multinucleated cells were counted as OCs. (D) Number of pits
formed on dentine slices in A was counted. Media of each culture were replaced with fresh media on day 3 (A–D). Results are representative of at least
three independent sets of similar experiments (A–D). All data are expressed as mean   SD of quadruplicate cultures. 
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results thus indicate that OSCAR is required for formation
of mature OCs from bone marrow precursor cells stimu-
lated by osteoblasts.
Although OSCAR–Fc inhibited osteoclastogenesis medi-
ated by osteoblasts, it did not inhibit the formation of ma-
ture OCs from the RAW264.7 cell line stimulated with sol-
uble TRANCE (data not shown). These results suggest that
when there is a supraphysiological amount of TRANCE
available and/or cells are CSF-1 independent as in the
RAW264.7 myeloid tumor cell line, OSCAR stimulation
may be bypassed in osteoclastogenesis. Moreover, when
OCs were derived from bone marrow cells by the combi-
nation of recombinant M-CSF and TRANCE in the ab-
sence of any osteoblasts/stromal cells, OSCAR–Fc did not
inhibit osteoclastogenesis (data not shown). Taken together,
OSCAR–Fc appears to affect osteoclastogenesis only when
it is induced by physiological levels of TRANCE and/or
M-CSF produced by osteoblasts in response to bone resorb-
ing hormones. Although future experiments are necessary
to understand how OSCAR/OSCAR-L interaction regu-
lates osteoclastogenesis, the level of TRANCE expression
in osteoblasts appears not to be regulated by OSCAR/OS-
CAR-L interaction (data not shown).
It is currently thought that the formation and activation
of OCs are tightly regulated by osteoblasts, which provide
at least two known essential factors for osteoclastogenesis,
TRANCE, and M-CSF. In addition, the ultimate osteo-
blast-induced osteoclastogenesis from bone marrow pre-
cursors are further influenced by various stromal cells that
produce different osteotropic factors (1, 2). These factors
can be divided into two groups: one influencing the activ-
ity of osteoblasts, e.g., TNF regulating the expression of
TRANCE in osteoblasts (1, 2, 9), and the other affecting
the OC precursors or OCs per se. The factors in the latter
group include TGF-
 
 
 
, which has been recently shown to
be a powerful costimulatory molecule for osteoclastogene-
sis induced by M-CSF and TRANCE (14–17, 41).
As reported previously, M-CSF and TRANCE together
appear to be sufficient to induce the differentiation of bone
marrow precursors, spleen cells, or blood monocytes to
mature OCs in vitro (2). However, the expression of
M-CSF, TRANCE, and their receptors are not limited to
bone cells. For example, M-CSF and TRANCE are im-
portant cytokines for the activity/viability of macrophages
and DCs (18). Despite this pleiotropy, OCs are not found
in most soft tissues. This raises question of why OCs are
not observed in various soft tissues. One possibility is that
there may be costimulatory molecules present only in the
bone. Alternatively, there is a powerful inhibitor of osteo-
clastogenesis in most soft tissues but not in bone.
Although most of the costimulatory molecules for osteo-
clastogenesis described to date (e.g., TGF-
 
 , TNF, or IL-
1) are not specific to the bone system (1, 2), it is still possi-
ble that there may be costimulatory receptors expressed
specifically on OCs and/or costimulatory factors specifi-
cally expressed on osteoblasts. As we have described in this
study, we have indeed identified a novel cell surface recep-
tor OSCAR specifically expressed in OCs, which appears
to regulate osteoclastogenesis. Moreover, a putative ligand
for OSCAR (OSCAR-L) is detected solely on osteoblasts
(Fig. 5). Therefore, this new receptor/ligand pair (OS-
CAR and OSCAR-L) may provide an evidence for the
role of various bone-specific costimulation pathways for
osteoclastogenesis to control the differentiation of OCs in
conjunction with the two essential factors M-CSF and
TRANCE, which are not bone specific. Finally, it is inter-
esting that the novel OC-specific costimulatory receptor
OSCAR is a member of the PIR/LRC family proteins
that have been shown to provide various costimulatory/in-
hibitory functions during the regulation of both innate and
adaptive immune responses (28, 37). OSCAR is unique
among the PIR/LRC family members in that it is not de-
tected in cells of the immune system such as macrophages
or DCs. It suggests that certain PIR/LRC family proteins
may have evolved to influence cells far beyond the im-
mune system, as it certainly controls bone metabolism as
shown in this study.
Under normal circumstances, the activity of OCs is inte-
grated with the requirements of calcium homeostasis and
skeletal morphogenesis and restructuring, while excessive
OC activity causes bone destruction in diseases such as
rheumatoid arthritis, Paget’s disease, periodontal disease,
chronic infections, and metastases of cancers (1, 2). Most
importantly, excessive osteoclastic activity is responsible for
the development of osteoporosis, a very common cause of
fracture, with consequent morbidity and mortality, in el-
derly people. Since OCs are the principal, if not the only,
cells which can resorb bone, the understanding of the mo-
lecular pathways leading to the differentiation and activa-
tion of OCs will help to make strides in the treatment and
prevention of osteoporosis as well as other diseases involv-
ing bone destruction. That OCs differentiate from mono-
cyte/macrophage lineage precursors which also give rise to
macrophages and DCs, key components of the immune
system, and that M-CSF and TRANCE, two essential fac-
Figure 5. Expression of OSCAR-L in osteoblasts. Primary calvarial os-
teoblasts are derived as described in the Materials and Methods. Surface
OSCAR-L expression on various cells was determined by FACS® analysis
using control human IgG1 (dotted lines) or OSCAR-Fc (solid lines) and
FITC-labeled anti–human IgG1. A thymoma cell line, BW5147, which
does not express OSCAR-L, was also shown here.208 A Novel Ig-like Receptor in Osteoclast
tors for osteoclastogenesis, also regulate cells of the immune
system, clearly indicate that many aspects of bone and the
immune system are shared at the cellular and molecular
levels. Such similarities in the molecular regulation of bone
and the immune system would make it rather difficult to
control pathological conditions of one or the other system
specifically. Therefore, an elucidation of various costimula-
tion pathways specific to bone but not to the immune sys-
tem, as shown in this study, will ultimately aid the design of
therapeutic approaches to bone diseases that do not com-
promise immune function.
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